溶瘤单纯疱疹病毒 1 治疗学：临床经验与进展机遇。
Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress.
机构信息
Dardinger Laboratory for Neuro-oncology and Neurosciences, Department of Neurological Surgery, James Comprehensive Cancer Center and The Ohio State University Medical Center, Columbus, Ohio, USA.
出版信息
Curr Pharm Biotechnol. 2012 Jul;13(9):1842-51. doi: 10.2174/138920112800958814.
Abstract
Oncolytic virotherapy with mutants derived from Herpes simplex virus (HSV) type 1 exhibit significant antitumor effects in preclinical models. Several mutants have now been tested in clinical trials for a variety of cancer types, and all have been found to be safe. While there have been hints of antitumor efficacy with prolonged survival in some cases compared with historical controls, dramatic responses have been elusive. We review the clinical experience published to date and discuss some of the biologic factors that may be limiting for virus infection and spread, as well as new strategies currently under development to enhance antitumor efficacy.
摘要
溶瘤病毒疗法使用从单纯疱疹病毒 1 型（HSV-1）衍生的突变株，在临床前模型中显示出显著的抗肿瘤作用。目前已有多种突变株在各种癌症类型的临床试验中进行了测试，均被证实是安全的。虽然与历史对照相比，某些情况下的生存期延长提示具有抗肿瘤疗效，但仍难以达到显著反应。我们回顾了迄今为止发表的临床经验，并讨论了一些可能限制病毒感染和传播的生物学因素，以及目前正在开发的增强抗肿瘤疗效的新策略。
相似文献
1
Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress.溶瘤单纯疱疹病毒 1 治疗学：临床经验与进展机遇。
Curr Pharm Biotechnol. 2012 Jul;13(9):1842-51. doi: 10.2174/138920112800958814.
2
Recent clinical experience with oncolytic viruses.近期溶瘤病毒的临床应用经验。
Curr Pharm Biotechnol. 2012 Jul;13(9):1834-41. doi: 10.2174/138920112800958904.
3
The Current Landscape of Oncolytic Herpes Simplex Viruses as Novel Therapies for Brain Malignancies.溶瘤单纯疱疹病毒作为治疗脑恶性肿瘤新型疗法的现状。
Viruses. 2021 Jun 17;13(6):1158. doi: 10.3390/v13061158.
4
Fusogenic oncolytic herpes simplex viruses as a potent and personalized cancer vaccine.作为一种有效且个性化的癌症疫苗，融合性溶瘤单纯疱疹病毒。
Curr Pharm Biotechnol. 2012 Jul;13(9):1773-85. doi: 10.2174/138920112800958832.
5
The molecular basis of herpesviruses as oncolytic agents.疱疹病毒作为溶瘤剂的分子基础。
Curr Pharm Biotechnol. 2012 Jul;13(9):1795-803. doi: 10.2174/138920112800958931.
6
Clinical development of oncolytic viruses in China.中国溶瘤病毒的临床开发。
Curr Pharm Biotechnol. 2012 Jul;13(9):1852-7. doi: 10.2174/138920112800958760.
7
Oncolytic virus therapy using genetically engineered herpes simplex viruses.使用基因工程单纯疱疹病毒的溶瘤病毒疗法。
Front Biosci. 2008 Jan 1;13:2060-4. doi: 10.2741/2823.
8
Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.新型溶瘤单纯疱疹病毒 1 VC2 在免疫活性 B16F10 衍生的小鼠黑素瘤模型中促进持久的、全身性抗黑素瘤肿瘤免疫反应和提高生存率。
J Virol. 2021 Jan 13;95(3). doi: 10.1128/JVI.01359-20.
9
Oncolytic HSV: Underpinnings of Tumor Susceptibility.溶瘤单纯疱疹病毒：肿瘤易感性的基础。
Viruses. 2021 Jul 20;13(7):1408. doi: 10.3390/v13071408.
10
[The Advances of Oncolytic Herpes Simplex Virus in Cancer Therapy].[溶瘤单纯疱疹病毒在癌症治疗中的进展]
Bing Du Xue Bao. 2016 Jul;32(4):516-22.
引用本文的文献
1
Biosafety and biohazard considerations of HSV-1-based oncolytic viral immunotherapy.基于单纯疱疹病毒1型的溶瘤病毒免疫疗法的生物安全和生物危害考量
Front Mol Biosci. 2023 Sep 12;10:1178382. doi: 10.3389/fmolb.2023.1178382. eCollection 2023.
2
Serendipitous synergism - an exceptional response to treatment with pembrolizumab in the course of a natural immunovirotherapy: a case report and review of the literature.意外协同作用——在自然免疫病毒疗法过程中对帕博利珠单抗治疗的特殊反应：一例病例报告及文献综述
Ther Adv Med Oncol. 2022 Oct 20;14:17588359221122729. doi: 10.1177/17588359221122729. eCollection 2022.
3
Emulating interactions between microorganisms and tumor microenvironment to develop cancer theranostics.模拟微生物与肿瘤微环境的相互作用，开发癌症治疗与诊断一体化策略。
Theranostics. 2022 Mar 14;12(6):2833-2859. doi: 10.7150/thno.70719. eCollection 2022.
4
Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of cytotoxic chemotherapy and other cytotoxic therapies in the management of progressive glioblastoma in adults.神经外科医师协会系统评价和循证指南更新：细胞毒性化疗和其他细胞毒性疗法在成人进展性胶质母细胞瘤治疗中的作用。
J Neurooncol. 2022 Jun;158(2):225-253. doi: 10.1007/s11060-021-03900-w. Epub 2022 Feb 23.
5
Viral vector-based gene therapies in the clinic.临床中基于病毒载体的基因疗法。
Bioeng Transl Med. 2021 Oct 20;7(1):e10258. doi: 10.1002/btm2.10258. eCollection 2022 Jan.
6
Organoid modeling of Zika and herpes simplex virus 1 infections reveals virus-specific responses leading to microcephaly.寨卡病毒和单纯疱疹病毒 1 感染的类器官模型揭示了导致小头畸形的病毒特异性反应。
Cell Stem Cell. 2021 Aug 5;28(8):1362-1379.e7. doi: 10.1016/j.stem.2021.03.004. Epub 2021 Apr 9.
7
Role of immunotherapy in Ewing sarcoma.免疫疗法在尤文肉瘤中的作用。
J Immunother Cancer. 2020 Dec;8(2). doi: 10.1136/jitc-2020-000653.
8
Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.新型溶瘤单纯疱疹病毒 1 VC2 在免疫活性 B16F10 衍生的小鼠黑素瘤模型中促进持久的、全身性抗黑素瘤肿瘤免疫反应和提高生存率。
J Virol. 2021 Jan 13;95(3). doi: 10.1128/JVI.01359-20.
9
Developing oncolytic through UL39 knockout by CRISPR-Cas9.通过CRISPR-Cas9敲除UL39来开发溶瘤病毒。
Iran J Basic Med Sci. 2020 Jul;23(7):937-944. doi: 10.22038/ijbms.2020.43864.10286.
10
Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966.用整合素 β1 阻断抗体 OS2966 增强溶瘤单纯疱疹病毒-1 的治疗效果。
Mol Cancer Ther. 2019 Jun;18(6):1127-1136. doi: 10.1158/1535-7163.MCT-18-0953. Epub 2019 Mar 29.
本文引用的文献
1
A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells.一种新型溶瘤单纯疱疹病毒，与磷酸肌醇 3-激酶/蛋白激酶 B 通路抑制剂协同作用，靶向神经胶质瘤干细胞。
Clin Cancer Res. 2011 Jun 1;17(11):3686-96. doi: 10.1158/1078-0432.CCR-10-3142. Epub 2011 Apr 19.
2
Suppression of soft tissue sarcoma growth by a host defense-like lytic peptide.一种宿主防御样裂解肽抑制软组织肉瘤生长。
PLoS One. 2011 Mar 31;6(3):e18321. doi: 10.1371/journal.pone.0018321.
3
Mechanism of HSV infection through soluble adapter-mediated virus bridging to the EGF receptor.单纯疱疹病毒通过可溶性衔接子介导的病毒桥接作用感染表皮生长因子受体的机制。
Virology. 2011 Apr 25;413(1):12-8. doi: 10.1016/j.virol.2011.02.014. Epub 2011 Mar 6.
4
Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy.ABC 型软骨素酶介导增强溶瘤病毒的传播和抗肿瘤疗效。
Clin Cancer Res. 2011 Mar 15;17(6):1362-72. doi: 10.1158/1078-0432.CCR-10-2213. Epub 2010 Dec 21.
5
Bispecific adapter-mediated retargeting of a receptor-restricted HSV-1 vector to CEA-bearing tumor cells.双特异性衔接子介导的受体受限型 HSV-1 载体对 CEA 阳性肿瘤细胞的重定向。
Mol Ther. 2011 Mar;19(3):507-14. doi: 10.1038/mt.2010.207. Epub 2010 Oct 5.
6
VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy.血管内皮生长因子阻断会降低全身性溶瘤单纯疱疹病毒在肿瘤中的摄取，但在病毒治疗后给予时会增强治疗效果。
Gene Ther. 2010 Jul;17(7):922-9. doi: 10.1038/gt.2010.82. Epub 2010 May 27.
7
Resistance of stem-like cells from neuroblastoma cell lines to commonly used chemotherapeutic agents.神经母细胞瘤细胞系中的干细胞样细胞对常用化疗药物的耐药性。
Pediatr Blood Cancer. 2010 Mar;54(3):361-8. doi: 10.1002/pbc.22351.
8
Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.瘤内注射 GM-CSF 编码溶瘤单纯疱疹病毒在 IIIc 期和 IV 期黑色素瘤患者中诱导的局部和远处免疫。
Ann Surg Oncol. 2010 Mar;17(3):718-30. doi: 10.1245/s10434-009-0809-6.
9
Identification of virus resistant tumor cell subpopulations in three-dimensional uveal melanoma cultures.三维葡萄膜黑色素瘤培养物中病毒抗性肿瘤细胞亚群的鉴定。
Cancer Gene Ther. 2010 Apr;17(4):223-34. doi: 10.1038/cgt.2009.73. Epub 2009 Nov 6.
10
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.编码粒细胞巨噬细胞集落刺激因子的第二代溶瘤性疱疹病毒在不可切除转移性黑色素瘤患者中的II期临床试验。
J Clin Oncol. 2009 Dec 1;27(34):5763-71. doi: 10.1200/JCO.2009.24.3675. Epub 2009 Nov 2.
Zotero 插件